Benzinga | Jul 8, 2021 09:10AM EDT

PureTech And Qualcomm Announce Collaboration To 'optimize use of Sonde's vocal biomarker technology' On The Qualcomm Snapdragon 888 And 778G 5G Mobile Platforms

PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Sonde Health ("Sonde"), today announced that it will collaborate with leading chipmaker Qualcomm Technologies, Inc. ("Qualcomm") to optimize use of Sonde's vocal biomarker technology on the flagship and high-tier Qualcomm(r) Snapdragon(tm) 888 and 778G 5G Mobile Platforms to help bring native, machine learning-driven vocal biomarker capabilities to mobile and IoT devices globally. The optimization has the potential to unlock several native health screening and monitoring applications on up to the hundreds of millions of mobile devices that use these Snapdragon mobile platforms.